COVID-19 Clinical Research Studies
COVID-19 Clinical Research Studies is a research topic within Infectious Diseases. Science Explorer counts 51k research works in it since 1950. 9.6% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the clinical characteristics, epidemiology, immune response, and treatment of Coronavirus Disease 2019 (COVID-19), caused by the SARS-CoV-2 virus. It covers topics such as thrombosis, ACE2 receptor, cytokine storm, and the pandemic's impact on various populations.
- Clinical Characteristics
- SARS-CoV-2
- Epidemiology
- Thrombosis
- Immune Response
- ACE2 Receptor
- Cytokine Storm
- Antiviral Treatment
- Pathophysiology
- Pandemic
- Research works
- 51k fractional, since 1950
- In the world top 10%
- 4.9k per year above
- Top-10% rate
- 9.6% share of its works in the world top 10%
- Growth, 2018-21 → 2022-25
- -3% the tick is no change
- Largest producer
United States
29% of the 10 largest, 2022-now
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead COVID-19 Clinical Research Studies research?
By volume, the United States and China publish the most (4.2k and 2.1k works in 2022-now).
By volume, 2022-now
- 1
United States 4.2k works
- 2
China 2.1k works
- 3
India 1.8k works
- 4
Italy 1.1k works
- 5
Iran 914 works
- 6
United Kingdom 895 works
- 7
Brazil 892 works
- 8
Türkiye 876 works
- 9
Spain 796 works
- 10
Japan 692 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead COVID-19 Clinical Research Studies research?
By volume in 2022-now, Harvard University publishes the most COVID-19 Clinical Research Studies research, followed by All India Institute of Medical Sciences and University of North Carolina at Chapel Hill.
By volume, 2022-now
- 1
Harvard University
United States 158 works
- 2
All India Institute of Medical Sciences
India 140 works
- 3
University of North Carolina at Chapel Hill
United States 139 works
- 4
Tehran University of Medical Sciences
Iran 106 works
- 5
Sağlık Bilimleri Üniversitesi
Türkiye 96 works
- 6
Johns Hopkins University
United States 88 works
- 7
Inserm
France 86 works
- 8
National Institutes of Health
United States 82 works
- 9
Russian Academy of Sciences
Russia 79 works
- 10
Universidade de São Paulo
Brazil 77 works
Who are the leading researchers in COVID-19 Clinical Research Studies?
The most-cited researchers publishing on COVID-19 Clinical Research Studies include David Moher, Christopher J L Murray and Freddie Bray.
- 1
David Moher
Canada 898k citations
- 2
Christopher J L Murray
United States 583k citations
- 3
Freddie Bray
France 550k citations
- 4
Zhong Lin Wang
United States 491k citations
- 5
Rob Knight
United States 468k citations
- 6
Simon Iain Hay
United States 452k citations
- 7
Theo Vos
United States 439k citations
- 8
George Davey Smith
United Kingdom 435k citations
- 9
Ali H. Mokdad
United States 429k citations
- 10
Mark J. Daly
United States 403k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is COVID-19 Clinical Research Studies research done?
The largest centres of COVID-19 Clinical Research Studies research in 2022-now are Tehran (Iran), Beijing (China), London (United Kingdom) and Moscow (Russia).
Where is the best place to study COVID-19 Clinical Research Studies?
Among universities, judged by research, University of Hong Kong, Harvard University and Karolinska Institutet score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.
Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.
Every institution in COVID-19 Clinical Research Studies, country by countryIs COVID-19 Clinical Research Studies research growing?
Output in 2022-2025 was 3% lower than in 2018-2021, peaking in 2021.
The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.
Its share of all research
Growing output can still be a shrinking share: all of science grows. This is COVID-19 Clinical Research Studies as a percentage of every work published that year, 0.076% in 2024.
Fractional works of COVID-19 Clinical Research Studies over all fractional works that year. How the balance of science has shifted.
How much of it reaches the world top 10%
Year by year.
Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.
Questions people ask
How much research is there on long COVID and COVID-19, and is it growing?
Output in 2022-2025 was 3% lower than in 2018-2021, peaking in 2021.
Is COVID-19 Clinical Research Studies research growing?Discussion
Ask a question or share a note about COVID-19 Clinical Research Studies. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.